Lymphomas
(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
- Details
ClinicalTrials.gov ID:
NCT01716806
Diagnosis Type:
Non-Hodgkins
USOR Number:
- Address
4715 Arapahoe Avenue
Boulder, CO 80303
P: (303) 385-2068